Resultats de la cerca - Vivek Roy

Refinar resultats
  1. 1
    Safety and Efficacy of <i>nab</i>-Paclitaxel in the Treatment of Patients with Breast Cancer

    Safety and Efficacy of <i>nab</i>-Paclitaxel in the Treatment of Patients with Breast Cancer per Prakash Vishnu, Vivek Roy

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer

    Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer per Vivek Roy, Edith A. Perez

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors

    Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors per Vivek Roy, Catherine M. Verfaillie

    Publicat 1999
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety

    Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficac... per Saurav Das, Sikander Ailawadhi, Taimur Sher, Vivek Roy, Andre Fernandez, Ricardo Parrondo

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

    Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531) per Vivek Roy, Betsy LaPlant, Gerald G. Gross, Charles Bane, Frances M. Palmieri

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Bone Marrow Transplantation for Diamond-Blackfan Anemia

    Bone Marrow Transplantation for Diamond-Blackfan Anemia per Vivek Roy, Waleska S. Pérez, Mary Eapen, Judith Marsh, Marcelo C. Pasquini, Ricardo Pasqüini, Mahmoud M. Mustafa, Christopher Bredeson

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis

    Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis per Ayalew Tefferi, Daniel K. Partain, Jeanne Palmer, James L. Slack, Vivek Roy, William J. Hogan, Mark Litzow, Rhett P. Ketterling, Mrinal M. Patnaik

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma per Shaji Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie S. Callander, Rafaël Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis

    Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis per Madiha Iqbal, Tea Reljic, Ernesto Ayala, Taimur Sher, Hemant S. Murthy, Vivek Roy, James M. Foran, Han W. Tun, Ambuj Kumar, Mohamed A. Kharfan‐Dabaja

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    A phase 2 study of vorinostat in acute myeloid leukemia

    A phase 2 study of vorinostat in acute myeloid leukemia per Élise Schaefer, Arturo Loaiza‐Bonilla, Mark Juckett, John F. DiPersio, Vivek Roy, James L. Slack, Wenting Wu, K. M. Laumann, Igor Espinoza‐Delgado, S. D. Gore

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

    Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer per Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein, Scott I. Bearman, Vivek Roy, Patrick C. McGrath, J. R. Caton, Nikhil C. Munshi, E. David Crawford

    Publicat 2001
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

    Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma per Kristen Detweiler Short, S. Vincent Rajkumar, Dirk R. Larson, Francis K. Buadi, Suzanne R. Hayman, Angela Dispenzieri, Morie A. Gertz, Shaji Kumar, Joseph Mıkhael, Vivek Roy, Robert A. Kyle, Martha Q. Lacy

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

    A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma per Patrick B. Johnston, David J. Inwards, Joseph P. Colgan, Betsy LaPlant, Brian Kabat, Thomas M. Habermann, Ivana N. Micallef, Luis F. Porrata, Stephen M. Ansell, Craig B. Reeder, Vivek Roy, Thomas E. Witzig

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

    Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance per Shaji Kumar, Jesús G. Berdeja, Rubén Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, S. Vincent Rajkumar, Paul G. Richardson

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

    A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma per Thomas E. Witzig, Kristina Laumann, Martha Q. Lacy, Suzanne R. Hayman, Angela Dispenzieri, Shaji Kumar, Craig B. Reeder, Vivek Roy, John A. Lust, Morie A. Gertz, Philip R. Greipp, Hani Hassoun, Sumithra J. Mandrekar, S. Vincent Rajkumar

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    <i>Cytokeratin-19</i> and <i>Mammaglobin</i> Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

    <i>Cytokeratin-19</i> and <i>Mammaglobin</i> Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Tria... per Monica M. Reinholz, Kathleen Kitzmann, Kathleen Tenner, David W. Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno‐Aspitia, Vivek Roy, Betsy LaPlant, Jake Allred, Philip J. Stella, Wilma L. Lingle, Edith A. Perez

    Publicat 2011
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities

    Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities per Sikander Ailawadhi, Ryan D. Frank, Mayank Sharma, Richa Menghani, M’hamed Temkit, Shumail M. Paulus, Nandita Khera, Shahrukh K. Hashmi, Pooja Advani, Abhisek Swaika, Aneel Paulus, Nabeel Aslam, Taimur Sher, Vivek Roy, Gerardo Colón‐Otero, Asher Chanan‐Khan

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia

    Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia per Vivek Kumar, Sikander Ailawadhi, Leyla Bojanini, Aditya Mehta, Suman Biswas, Taimur Sher, Vivek Roy, Prakash Vishnu, Julian A. Marin‐Acevedo, Victoria R. Alegria, Aneel Paulus, Sonikpreet Aulakh, Madiha Iqbal, Rami Manochakian, Winston Tan, Asher Chanan‐Khan, Meghna Ailawadhi

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis

    Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis per Tania Jain, Katie L. Kunze, M’hamed Temkit, Daniel K. Partain, Mrinal M. Patnaik, James L. Slack, Nandita Khera, William J. Hogan, Vivek Roy, Pierre Noël, José F. Leis, Lisa Z. Sproat, Veena Fauble, Ruben A. Mesa, Jeanne Palmer

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research

    Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Tr... per Steven Z. Pavletic, Issa F. Khouri, Michael Haagenson, Roberta King, Philip J. Bierman, Michael R. Bishop, Michael J. Carston, Sergio Giralt, Arturo Molina, Edward A. Copelan, Olle Ringdén, Vivek Roy, Karen K. Ballen, Douglas R. Adkins, Philip L. McCarthy, Daniel J. Weisdorf, Emili Montserrat, Claudio Anasetti

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: